What Yatiri Bio does

Yatiri Bio is a San Diego-based biotechnology company founded in 2020 that delivers AI-driven proteomics platforms to the biopharmaceutical industry for oncology drug discovery and patient stratification. Its core technology stack integrates high-resolution mass spectrometry-based proteomics (8,000-11,000 proteins per sample), patient-derived ex vivo cellular models (ProteoModels™), a deep learning architecture, and an interactive data portal (ProteoBrowser™). The flagship product, ProteoCharts™, uses deep neural networks to combine unbiased proteomic profiles with clinical metadata and drug response data from proprietary cellular models to predict patient response and identify resistance pathways. The company's primary therapeutic focus is acute myeloid leukemia (AML), with planned expansion into MDS, ovarian, prostate, breast, and colorectal cancers, supported by a pipeline of 7 peer-reviewed publications and an AML dataset exceeding 200 patient samples, 40 functional ex vivo models, and 5,500+ dose-response curves across 50 compounds.

Yatiri Bio generates revenue primarily through milestone-based co-development and licensing partnerships with biopharmaceutical companies, complemented by discovery proteomics services and non-dilutive grant funding. Notable agreements include a collaboration with Foghorn Therapeutics (clinical and sales milestones valued at over $40 million) and an exclusive global option-to-license agreement with Oscotec for denfivontinib. The company's GTM motion is enterprise field sales targeting pharma business development and clinical development leaders, with co-development deals and CRO-style service agreements as the primary revenue mechanics. Following the November 2025 acquisition of NGeneBioAI, Yatiri Bio operates a CLIA/CAP-certified laboratory facility, enabling development of proprietary Laboratory Developed Tests (LDTs) for clinical trial patient stratification — a higher-margin revenue stream layered on top of the existing services business.

The company is venture-backed (specific investors not disclosed) and operates with 11-50 employees from its San Diego headquarters at 6335 Nancy Ridge Dr. Founders Pilgrim Jackson (Ph.D., ex-Celgene), Mahan Abbasian (ex-BMS/Celgene), Afshin Mahmoudi (ex-Celgene), and Raman Afshar (Ph.D., also VP at AnaSpec) bring deep proteomics and drug discovery experience. The scientific advisory board includes John R. Yates III (SEQUEST inventor), Jill Mesirov (GSEA creator), and Jennifer Van Eyk, providing strong scientific credibility. The company's value proposition — articulated as a 15-20% reduction in development timelines and 5x increase in likelihood of regulatory success versus industry benchmarks — rests on the premise that proteomic data, rather than genomics alone, more accurately captures functional disease biology and predicts therapeutic response.

Name

Yatiri Bio

Legal name

Yatiri Bio Inc.

Website

https://yatiribio.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Yatiri Bio is a San Diego-based biotechnology company that uses AI-driven proteomics and patient-derived cellular models to help biopharmaceutical companies stratify oncology patients and de-risk clinical trials, with a primary focus on AML and expansion into solid tumors.

Ownership category

akta.pro rank

Product category

Biomarker Discovery and Proteomics Services

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Medical and Diagnostic Laboratories (6215)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071)

akta.pro primary industry

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE)

akta.pro secondary industries

Proteomics & Mass Spectrometry Services (HLAGANAB), Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), Biomarker Discovery & Validation (omics, assay feasibility, clinical validation) (HLAAAMAA), Translational Medicine & Biomarkers (HLAIALAF)

Keywords

• Proteomics services
• Biomarker discovery
• Patient stratification
• Drug discovery platform
• Mass spectrometry analysis

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales, Supply Chain

Revenue model

1. Pharma Partnership Milestone Payments: Yatiri Bio uses a pharma partnership model with payments based on discovery, development, regulatory, and commercial milestones. Collaborations include clinical and sales milestones valued at over $40 million (Foghorn agreement) and option-to-license arrangements (Oscotec denfivontinib agreement).
2. Non-Dilutive Grant Funding: The company secures non-dilutive funding from prominent organizations including the Gates Foundation (proteomics interoperability project) and CDMRP/US Department of Defense ($110K Phase 1 grant for hypopharyngeal cancer).
3. Laboratory Developed Tests (LDTs) and Companion Diagnostics: Leveraging its CLIA/CAP-accredited facility, Yatiri Bio develops proprietary Laboratory Developed Tests (LDTs) that stratify patients for clinical trials, creating a de-risked development pathway and potential companion diagnostic revenue.
4. Discovery Proteomics Services: The company offers discovery proteomics services including global proteomics on multiple sample types (cell lines, organoids, tissue, clinical samples), PTM analysis, and interactive data portal access through ProteoBrowser™.

Go-to-market motion3 records

Distribution channels2 records

Marketing channels5 records

Core offering

Yatiri Bio is a biotechnology company that delivers AI-driven proteomics-based biomedical data solutions to the pharmaceutical industry, combining high-resolution mass spectrometry proteomics, deep learning, and patient-derived cellular models to enable biomarker-driven patient stratification for oncology clinical trials. The company's core offerings include its ProteoCharts™ patient stratification platform, ProteoModels™ patient-derived cellular models, ProteoBrowser™ interactive data portal, alongside discovery proteomics and efficacy model services for biopharma partners. It operates a CLIA/CAP-accredited laboratory for developing Laboratory Developed Tests (LDTs) for clinical trial patient selection.

Product overview

Yatiri Bio offers a unified proteomics-driven precision medicine platform centered on ProteoCharts™ (AI-driven patient stratification), ProteoModels™ (patient-derived cellular models), and ProteoBrowser™ (interactive data portal). These core products are complemented by Discovery Proteomics services and Efficacy Models for drug testing. The company integrates mass spectrometry-based proteomics, deep learning, and patient-derived ex vivo systems to accelerate oncology drug discovery and enable precise patient selection. Their AML Platform represents a disease-specific implementation combining all core capabilities for acute myeloid leukemia research.

Differentiator

Problem solved

Functional benefit

Brands

• ProteoCharts: AI-driven proteomic platform that integrates unbiased proteomic profiling with clinical data and functional testing in proprietary patient-derived models to create predictive stratification models for disease landscapes.
• ProteoModels
• ProteoBrowser
• ProteoPathway

Products and services

• ProteoCharts™
• ProteoModels™
• ProteoBrowser™
• ProteoPathway™
• Discovery Proteomics
• Efficacy Models
• AML Platform

Quantifiable outcome

• 100% concordance between biomarker-guided predictions and observed clinical outcomes in a blinded retrospective validation study for AML/MDS drug response
• +4 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature7 records

Partnerships

Ten partnerships are on record, tiered core and minor.

• Oscotec, Inc.coreOEM/ Whitelabel/ Licensing Partner · 24 March 2026Yatiri Bio entered into an exclusive global option to license agreement with Oscotec to develop and commercialize denfivontinib (SKI-G-801), a potent multikinase inhibitor for AML treatment. Yatiri Bio identified a novel FLT3-independent biomarker profile using its ProteoCharts platform to identify patients highly responsive to denfivontinib. The company is developing a proprietary LDT to stratify patients for upcoming clinical trials.
• Foghorn TherapeuticscoreStrategic or Co-development Partner · 10 February 2026Yatiri Bio and Foghorn Therapeutics signed a collaboration agreement for the further clinical development of FHD-286 (camibirstat), a novel BAF complex inhibitor for R/R AML and MDS. Yatiri Bio's ProteoCharts platform achieved 100% concordance in a blinded retrospective validation study predicting treatment response from pre-dose peripheral blood samples. The agreement includes clinical and sales milestones valued at over $40 million, with Foghorn supplying material for further clinical development.
• NGeneBioAI, Inc.coreTechnology or Integration · 29 November 2025Yatiri Bio acquired NGeneBioAI, a San Diego-based company specializing in plasma proteomics and AI-powered diagnostics. The acquisition transferred all NGeneBioAI assets, proprietary technologies, commercial agreements, and intellectual property to Yatiri Bio, including CLIA- and CAP-certified laboratory infrastructure, enhancing Yatiri Bio's AI-proteomics platform and expanding its capability to develop LDTs.
• OrdaōscoreStrategic or Co-development Partner · 15 December 2022Yatiri Bio and Ordaōs entered a joint development agreement to create novel therapeutics for high-risk subsets of AML. Yatiri Bio uses its patient proteome data and matched ex vivo models to identify two cell surface therapeutic targets, while Ordaōs uses its Ordaōs Design Engine to create in silico de novo protein candidates for in vitro validation. Target leads will be tested in Yatiri Bio's ProteoModels and jointly developed for IND submission.
• Fred Hutch Cancer Center (FHCC)coreStrategic or Co-development PartnerYatiri Bio and Fred Hutch Cancer Center entered a Research Collaboration Agreement using AML patient proteomic data from the Stirewalt lab processed through Yatiri Bio's bioinformatic pipeline. Goals include finding correlations between proteomic data and disease progression, stratifying patient samples into groups correlated with oncology models, uncovering biomarkers and pathways, investigating prognostic capabilities, and discovering novel therapeutic targets in AML.
• South Coast Gynecologic Oncology, Inc. (SCGOI)minorStrategic or Co-development PartnerYatiri Bio entered a collaboration agreement with SCGOI in ovarian cancer for discovery of novel predictive biomarkers and new targets using global proteomics data generated from fresh and derivatized ovarian cancer samples. Yatiri Bio's technology facilitates matching of molecularly defined patient subsets to tailored cellular model systems.
• Dr. Derek Stirewalt (Fred Hutch)coreStrategic or Co-development PartnerResearch collaboration agreement in AML with Dr. Derek Stirewalt from Fred Hutch Cancer Center focused on discovery of novel AML prognostic and predictive biomarkers as well as unique therapeutic targets. Dr. Stirewalt leads the Fred Hutch/UW Hematopoietic Diseases Repository, a national toll gate for AML biospecimens.
• Professor John R. Yates III (The Scripps Research Institute)coreOthersProfessor John Yates joined Yatiri Bio's advisory board. As a pioneer in proteomics and inventor of SEQUEST algorithm and shotgun proteomics technique, his expertise in bioinformatics, methods development, and biological applications has been vital to Yatiri Bio's IP development.
• Professor Jill Mesirov (UC San Diego / Broad Institute)coreOthersProfessor Jill Mesirov joined Yatiri Bio's advisory board. She supports Yatiri Bio's machine learning efforts to integrate disparate data streams and extract actionable knowledge from proteomics data. She is a senior institute fellow at the Broad Institute and pioneered tools including GenePattern and Gene Set Enrichment Analysis (GSEA).
• Professor Jennifer Van Eyk (Cedars-Sinai)minorOthersProfessor Jennifer Van Eyk joined Yatiri Bio's advisory board. She is a renowned clinical proteomics scientist serving as Erika Glazer Chair in Women's Heart Health at Cedars-Sinai. She supports Yatiri Bio's proteomics efforts related to clinically relevant biomarker development.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Seer: Seer is a direct peer operating a proprietary proteomics platform (Proteograph) that uses nanoparticle-based enrichment plus mass spectrometry for deep, unbiased protein profiling. Both companies target pharma drug discovery and translational research with AI-augmented proteomics, though Seer is broader across indications while Yatiri is more vertically focused on oncology patient stratification.
• Somalogic: Somalogic operates an aptamer-based proteomics platform (SomaScan) for biomarker discovery and pharma research partnerships. It is comparable to Yatiri as a proteomics platform serving pharma with high-plex protein measurements; Somalogic is more established commercially but applies a different measurement chemistry, and is now part of Standard BioTools.
• Olink: Olink provides antibody-based proximity extension assay proteomics solutions used widely across pharma biomarker discovery and clinical research. It is comparable to Yatiri as a proteomics platform serving biopharma customers for patient stratification and target discovery, though Olink's affinity-based approach differs from Yatiri's unbiased mass spectrometry pipeline.
• Nautilus Biotechnology: Nautilus Biotechnology is developing a single-molecule protein analysis platform aimed at deep, reproducible proteomic profiling for pharma research and biomarker discovery. It is comparable to Yatiri as a next-generation proteomics platform targeting pharma drug development workflows, although Nautilus focuses on platform instruments rather than service-based patient stratification.

Emerging players

• Cell Signaling Technology: Cell Signaling Technology is a leading producer of antibodies and proteomics reagents used widely in pharma research and clinical diagnostics, with growing services in proteomics profiling. It is comparable to Yatiri as a proteomics-focused life sciences organization serving pharma and translational researchers, though CST's primary business is reagents rather than integrated AI services.
• Quanterix: Quanterix develops ultra-sensitive single-molecule array (Simoa) immunoassay technology for protein biomarker detection in pharma research and clinical applications. It is comparable to Yatiri as a proteomics platform serving pharma for biomarker-driven decision-making, though Quanterix's affinity-based assay chemistry differs from Yatiri's mass spectrometry-based approach.

Broad incumbents

• Thermo Fisher Scientific: Thermo Fisher Scientific provides mass spectrometry instruments, proteomics workflows, and CRO services through its PPD division, including pharma biomarker discovery and clinical trial services. It is comparable to Yatiri through its proteomics instrument platform and pharma services, though Thermo Fisher operates across the entire life sciences stack rather than focusing on patient stratification.
• Bio-Techne: Bio-Techne offers a broad portfolio of proteomics reagents, assays, and analytical tools used by pharma and academic researchers for biomarker discovery. It is comparable to Yatiri as a life sciences tools company serving proteomics-driven translational research, though Bio-Techne's primary revenue comes from reagent catalog products rather than integrated AI services.
• Evotec: Evotec is a large contract research organization offering drug discovery and development services across modalities, including proteomics and patient-derived model capabilities. It is comparable to Yatiri as a pharma-facing discovery services provider integrating proteomics and cellular models, though Evotec operates at far greater scale and across a much broader service portfolio.
• Charles River Laboratories: Charles River Laboratories provides preclinical CRO services including proteomics, biomarker discovery, and patient-derived model services for pharma clients. It is comparable to Yatiri through its discovery services and biosample analysis capabilities, though Charles River's offerings span the full preclinical pipeline rather than specializing in AI-driven proteomics stratification.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/yatiri-bio-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Yatiri Bio